Published in Eur Arch Otorhinolaryngol on February 14, 2013
Extracellular vesicles: potential applications in cancer diagnosis, prognosis, and epidemiology. BMC Clin Pathol (2015) 1.02
The use of rapid and cost-effective blood-based biomarkers in combination with tumour TNM stage for individual head and neck cancer patient treatment selection. Med Oncol (2017) 0.75
Perioperative circulating tumor cell detection: Current perspectives. Cancer Biol Ther (2016) 0.75
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Dissecting the metastatic cascade. Nat Rev Cancer (2004) 6.32
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst (2008) 5.74
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol (2000) 5.26
Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res (2006) 4.95
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer. Clin Cancer Res (2006) 4.86
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol (2010) 3.26
Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer. J Oncol (2009) 3.14
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med (2010) 2.02
Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol (2010) 1.96
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol (2009) 1.71
Detection of EpCAM-Negative and Cytokeratin-Negative Circulating Tumor Cells in Peripheral Blood. J Oncol (2011) 1.60
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer Res (2011) 1.36
Significance of circulating tumor cells in patients with squamous cell carcinoma of the head and neck: initial results. Arch Otolaryngol Head Neck Surg (2010) 1.32
Disseminated tumor cells of breast cancer patients: a strong prognostic factor for distant and local relapse. Clin Cancer Res (2008) 1.30
Confocal images of circulating tumor cells obtained using a methodology and technology that removes normal cells. Mol Pharm (2009) 1.20
Multiparameter analysis, including EMT markers, on negatively enriched blood samples from patients with squamous cell carcinoma of the head and neck. PLoS One (2012) 1.20
Dissemination of cancer cells into circulation occurs by incisional biopsy of oral squamous cell carcinoma. J Oral Pathol Med (2000) 1.10
Minimal residual disease in head and neck cancer. Cancer Metastasis Rev (1999) 1.09
Detection of rare disseminated tumor cells identifies head and neck cancer patients at risk of treatment failure. Clin Cancer Res (2003) 1.08
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch system. Head Neck (2011) 1.02
Clinical significance of micrometastatic cells detected by E48 (Ly-6D) reverse transcription-polymerase chain reaction in bone marrow of head and neck cancer patients. Clin Cancer Res (2004) 0.96
The presence of circulating tumor cells (CTCs) correlates with lymph node metastasis in nonresectable squamous cell carcinoma of the head and neck region (SCCHN). Ann Oncol (2011) 0.92
Molecular mechanisms of metastasis. J Surg Oncol (2011) 0.90
Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival. Eur J Cancer (2012) 0.89
[Detection and quantification of circulating tumor cells in peripheral blood in patients with colon cancer]. Med Clin (Barc) (2007) 0.89
[Micrometastases in bone marrow of patients with cancers in the head and neck area]. Laryngorhinootologie (1994) 0.85
Reverse transcriptase polymerase chain reaction study to evaluate dissemination of cancer cells into circulation after incision biopsy in oral squamous cell carcinoma. Indian J Dent Res (2008) 0.83
Epithelial cells in the peripheral blood of patients with cancer of the head and neck: incidence, detection and possible clinical significance. Radiother Oncol (2001) 0.82
Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie (2004) 0.81
Identification of circulating tumor cells: a prognostic marker in squamous cell carcinoma of the head and neck? Future Oncol (2011) 0.77
Detection of micrometastatic tumor cells in head and neck squamous cell carcinoma. A possible predictor of recurrences? Saudi Med J (2007) 0.76
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98
Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A (1999) 3.74
In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood (2000) 3.57
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med (1997) 2.03
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol (2000) 1.99
Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy (1999) 1.83
Amino acid analysis at the picomole level. Application to the C-terminal sequence analysis of polypeptides. Biochem J (1981) 1.76
Expression of the serpin serine protease inhibitor 6 protects dendritic cells from cytotoxic T lymphocyte-induced apoptosis: differential modulation by T helper type 1 and type 2 cells. J Exp Med (2001) 1.62
p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene (1993) 1.62
Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med (2000) 1.56
Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino)azobenzenesulfonyl chloride. Anal Chem (1986) 1.52
Effectiveness of radical systematic mediastinal lymphadenectomy in patients with resectable non-small cell lung cancer: results of a prospective randomized trial. Ann Surg (1998) 1.50
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res (2001) 1.48
p53 in non-small-cell lung cancer. J Natl Cancer Inst (1994) 1.46
Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res (1999) 1.43
[Tissue microarrays. Value of immunohistochemical proliferation markers for serial investigations of head and neck cancer]. HNO (2004) 1.41
PLK (polo-like kinase), a new prognostic marker for oropharyngeal carcinomas. Int J Cancer (2000) 1.37
MAGE-A gene expression pattern in primary breast cancer. Cancer Res (2001) 1.34
Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment. Br J Cancer (2008) 1.34
Tumor-antigen heterogeneity of disseminated breast cancer cells: implications for immunotherapy of minimal residual disease. Int J Cancer (1999) 1.33
Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer (1991) 1.31
Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene (2006) 1.24
Amino acid analysis in the picomole range by precolumn derivatization and high-performance liquid chromatography. Methods Enzymol (1983) 1.24
Prognostic significance of bone marrow micrometastases in patients with gastric cancer. J Clin Oncol (1996) 1.22
Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. J Clin Oncol (1994) 1.18
RT-PCR-based detection of occult disseminated tumor cells in peripheral blood and bone marrow of patients with solid tumors. An overview. Ann N Y Acad Sci (2000) 1.16
Radical systematic mediastinal lymphadenectomy in non-small cell lung cancer: a randomized controlled trial. Br J Surg (1994) 1.15
Differentiation of benign and malignant parotid tumors using deconvolution-based perfusion CT imaging: feasibility of the method and initial results. Eur J Radiol (2007) 1.07
Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer. J Clin Oncol (1999) 1.06
Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer (2010) 1.06
Detection of disseminated lung cancer cells in lymph nodes: impact on staging and prognosis. Ann Thorac Surg (1996) 1.00
Overexpression of matrix metalloproteinase 2 predicts unfavorable outcome in early-stage non-small cell lung cancer. Clin Cancer Res (2000) 1.00
Impact of radical systematic mediastinal lymphadenectomy on tumor staging in lung cancer. Ann Thorac Surg (1995) 1.00
Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res (1996) 1.00
Optimized speech understanding with the continuous interleaved sampling speech coding strategy in patients with cochlear implants: effect of variations in stimulation rate and number of channels. Ann Otol Rhinol Laryngol (2000) 1.00
Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res (1999) 0.99
Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse. J Clin Oncol (2001) 0.99
A new method for the selective isolation of cysteine-containing peptides. Specific labelling of the thiol group with a hydrophobic chromophore. Biochem J (1983) 0.99
Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol (2010) 0.98
Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: association with early lymphatic spread of tumour cells. Eur J Cancer (1996) 0.98
The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer (2001) 0.97
Micrometastatic bone marrow involvement: detection and prognostic significance. Med Oncol (1999) 0.96
Sequence determination of eglin C using combined microtechniques of amino acid analysis, peptide isolation, and automatic Edman degradation. Anal Biochem (1983) 0.95
Results of cochlear implantation in patients with severe to profound hearing loss--implications for patient selection. Audiology (1999) 0.95
Bazex syndrome (acrokeratosis paraneoplastica). Eur Arch Otorhinolaryngol (1998) 0.94
A mathematical model of erythropoiesis in mice and rats. Part 1: Structure of the model. Cell Tissue Kinet (1989) 0.94
Immunocytochemical detection and phenotypic characterization of micrometastatic tumour cells in bone marrow of patients with prostate cancer. Urol Res (1994) 0.94
The cross-reactive idiotype of anti-4-azobenzenearsonate hybridoma-derived antibodies in A/J mice constitutes multiple heavy chains. Hoppe Seylers Z Physiol Chem (1980) 0.93
Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: detection and prognostic significance. World J Surg (1996) 0.92
[Infusion therapy in sudden deafness. Reducing the risk of pruritus after hydroxyethyl starch and maintaining therapeutic success--a prospective randomized study]. Laryngorhinootologie (1995) 0.92
Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer. Cancer Res (2000) 0.91
Direct analysis of the disulfide content of proteins: methods for monitoring the stability and refolding process of cystine-containing proteins. Anal Biochem (1991) 0.91
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. Eur Arch Otorhinolaryngol (2012) 0.90
Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg (1995) 0.90
Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg (2002) 0.90
Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry (1993) 0.90
Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg (1996) 0.90
Expression of CD44 isoforms in renal cell tumors. Positive correlation to tumor differentiation. Am J Pathol (1996) 0.90
A novel non-radioactive cellular cytotoxicity test based on the differential assessment of living and killed target and effector cells. J Immunol Methods (1995) 0.89
Expression and prognostic significance of immunoregulatory molecules in esophageal cancer. Int J Cancer (1997) 0.89
Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int (2003) 0.89
Occult epithelial tumor cells detected in bone marrow by an enzyme immunoassay specific for cytokeratin 19. Int J Cancer (1997) 0.88
Clinical significance of occult metastatic cells in bone marrow of breast cancer patients. Oncologist (2001) 0.88
Isolated tumor cells in bone marrow predict reduced survival in node-negative non-small cell lung cancer. Ann Thorac Surg (1999) 0.87
Primary structure and function of novel O-glycosylated hirudins from the leech Hirudinaria manillensis. Biochemistry (1992) 0.87
Expression of insulin-like growth factor II mRNA-binding protein 3 in squamous cell carcinomas of the head and neck. J Oral Pathol Med (2012) 0.86
Patterns of metastatic spread in early breast cancer. Breast (2013) 0.84
Diagnosis of liver cirrhosis with US: receiver-operating characteristic analysis of multidimensional caudate lobe indexes. Radiology (1989) 0.84
A complete separation of dimethylaminoazobenzenesulphonyl-amino acids. Amino acid analysis with low nanogram amounts of polypeptide with dimethylaminoazobenzenesulphonyl chloride. Biochem J (1982) 0.84
Human papilloma virus in locally advanced stage III/IV squamous cell cancer of the oropharynx and impact on choice of therapy. Oral Oncol (2010) 0.84
p53 gene mutations are not required for early dissemination of cancer cells. Proc Natl Acad Sci U S A (1999) 0.84
Canine visceral leishmaniasis caused by Leishmania infantum in Senegal: risk of emergence in humans? Microbes Infect (2010) 0.84
Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. J Natl Cancer Inst (1996) 0.84
[Quality assessment according to DIN EN ISO 9001:2000: certification in a university ENT department]. HNO (2006) 0.83
Immunocytologic detection of isolated tumor cells in bone marrow of patients with squamous cell carcinomas of the head and neck region. Int J Oral Maxillofac Surg (1995) 0.83
Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol (2001) 0.83
Expression of major histocompatibility class I and class II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinomas: frequency and prognostic significance. Eur J Cancer (1994) 0.83
Clinical utility of determination of HER-2/neu and EGFR fragments in serum of patients with metastatic breast cancer. Int J Biol Markers (2006) 0.83
Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1998) 0.82
Separation, purification, and sequence identification of TGF-beta 1 and TGF-beta 2 from bovine milk. J Protein Chem (1991) 0.82
Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat (1998) 0.82
BM micrometastases and circulating tumor cells in breast cancer patients: where have we been, where are we now and where does the future lie? Cytotherapy (2005) 0.82
Biological characteristics of micrometastatic cancer cells in bone marrow. Cancer Metastasis Rev (1999) 0.82
Use of representational difference analysis and cDNA arrays for transcriptional profiling of tumor tissue. Ann N Y Acad Sci (2000) 0.82
Micrometastatic tumour cells in bone marrow in colorectal cancer. Lancet (1993) 0.82
A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom (2006) 0.82
A mathematical model of erythropoiesis in mice and rats. Part 2: Stimulated erythropoiesis. Cell Tissue Kinet (1989) 0.81
Ketone kinetics and D-(-)-3-hydroxybutyrate-induced inhibition of feeding in rats. Physiol Behav (1985) 0.81
Elastase-cathepsin G inhibitors eglin b and eglin c differ by a single Tyr----His substitution. A micro-method for the identification of amino-acid substitution. Biol Chem Hoppe Seyler (1985) 0.81
Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cells. Clin Cancer Res (2000) 0.81
Prognostic relevance of volumetric analysis in tumour specimens of hypopharyngeal cancer. Clin Otolaryngol (2007) 0.80
Cross-reactive staining of normal bone-marrow cells by monoclonal antibody 2E11. Int J Cancer (1999) 0.80
New treatment strategies for HPV-positive head and neck cancer. Eur Arch Otorhinolaryngol (2013) 0.80
Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res (2001) 0.80
Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer. J Gastrointest Surg (2006) 0.80
Amino acid sequences of antibody light chain variable regions of pedigreed rabbits: kappa light chain K49-501 (allotype b4 anti-streptococcal group A-variant polysaccharide antibody). Hoppe Seylers Z Physiol Chem (1979) 0.80
[Quality management: reduced waiting time and enhanced efficiency in a university ear, nose, and throat outpatient department]. HNO (2007) 0.80